- Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Double-Blind, Phase II Study of BMS-986315 and Nivolumab in Combination with Chemotherapy Versus Nivolumab in Combination with Chemotherapy as First-line Treatment for Participants with Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with two different drug approaches to see which works best and if there are side effects. Doctors want to find better treatments for non-small cell lung cancer.
For: Non-small Cell Lung CancerSpain · Romania · Italy - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2 Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Investigational Agents in Combination with Etoposide and Cisplatin or Carboplatin for the First-Line Treatment of Participants with Extensive-Stage Small Cell Lung Cancer (KEYNOTE-B99)
This study is looking at new ways to treat advanced small cell lung cancer for the first time. It combines Pembrolizumab with other medications to see how well they work together and if they are safe.
For: First-line treatment of participants with extensive-stage small cell lung cancerPoland · Hungary · Spain - Active not recruitingPHASE1, PHASE2
GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors
This study is testing a new cancer medicine, GEN1042, both by itself and with other treatments. It's for people with certain advanced solid tumours where standard treatments haven't worked or aren't available. The main goals are to check its safety and see how well it fights cancer.
For: Malignant Solid Tumor · Non-Small Cell Lung Cancer (NSCLC) · Colorectal Cancer (CRC)United States · Denmark · France - RecruitingPHASE3
High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)
This study looks at new ways to treat high-risk neuroblastoma, a type of cancer, in children and young people. Researchers are testing different combinations of chemotherapy and radiation to find the most effective treatments to help patients live longer and healthier lives.
For: High-Risk Neuroblastoma · Patient With Insufficient Response ChemoimmunotherapyAustralia · Austria · Belgium - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3, Randomized Study of Nivolumab plus Ipilimumab in Combination with Chemotherapy vs Chemotherapy alone as First Line Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC)
This study is testing if adding two new drugs, nivolumab and ipilimumab, to standard chemotherapy works better than chemotherapy alone for advanced lung cancer. It seeks to understand if this new combination helps people live longer.
For: Stage IV Non-Small Cell Lung Cancer (NSCLC)Spain · Ireland · Poland - RecruitingPHASE2, PHASE3
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
This study is testing a new drug, iza-bren, for advanced triple-negative breast cancer or ER-low, HER2-negative breast cancer. It compares iza-bren with standard chemotherapy in patients who haven't had previous treatment for advanced disease and can't receive certain immunotherapy drugs.
For: Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE2
Mirvetuximab Soravtansine (MIRV) With Carboplatin in Second-line Treatment of Folate Receptor Alpha (FRα) Expressing, Platinum-sensitive Epithelial Ovarian Cancer
This study looks at a new drug, mirvetuximab soravtansine, with carboplatin for certain types of ovarian, primary peritoneal, or fallopian tube cancer. It's for people whose cancer has come back but responded well to previous platinum-based chemotherapy.
For: High Grade Ovarian Cancer · Primary Peritoneal Cancer · Fallopian Tube CancerUnited States · Belgium · Canada - Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
First-In-Human, Open-Label, Dose Escalation Trial with Expansion Cohorts to Evaluate the Safety and Preliminary Efficacy of GEN1055 as Monotherapy and as Combination Therapy in Subjects with Malignant Solid Tumors.
This study is testing a new medicine, GEN1055, for various cancers. It's looking at how safe it is, what side effects it causes, and how well it works, both on its own and with other cancer treatments like Pemetrexed and Pembrolizumab.
For: Malignant Solid TumorsSpain - Active not recruitingPHASE2
The BARCODE 2 Study - The Use of Genetic Profiling to Guide Prostate Cancer Treatment
This study looks at how a drug called carboplatin works for men with advanced prostate cancer. We want to see if changes in their genes affect how well the treatment works. It could help us find better ways to treat prostate cancer in the future.
For: Hormone Refractory Prostate CancerUnited Kingdom - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase III, Randomized, Open-Label Study of Pralsetinib versus Standard Of Care for First-Line Treatment of RET Fusion-Positive, Metastatic Non-Small Cell Lung Cancer
This study is looking at a new drug called Pralsetinib for advanced lung cancer where a specific genetic change (RET fusion) is present. It compares Pralsetinib to standard treatments to see if it works better or has fewer side effects for people who haven't had treatment for this type of cancer before.
For: RET fusion−positive · metastatic Non-Small Cell Lung CancerFrance · Netherlands · Belgium - RecruitingPHASE3
A Study to Investigate the Efficacy and Safety of Dato-DXd With or Without Osimertinib Compared With Platinum Based Doublet Chemotherapy in Participants With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer
This study looks at new treatments for a type of lung cancer where standard treatment has stopped working. It compares a drug called Dato-DXd, alone or with osimertinib, against usual chemotherapy to see which helps patients live longer without their cancer getting worse.
For: Metastatic Non-small Cell Lung CancerUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
ABCSG 45: A prospective, open, randomized, phase II study of carboplatin/olaparib in the pre-operative treatment of patients with triple-negative primary breast cancer which exhibit the features of positive homologous recombination deficiency (HRD) status
This study looks at a new combination treatment for a specific type of early breast cancer. It compares giving a drug called olaparib with carboplatin before surgery, with a standard chemotherapy. The aim is to see if the new treatment shrinks the cancer more effectively.
For: Early invasive triple negative breast cancer with positive HRD status (acc. to Myriad mychoice© test)Austria - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Study of Pembrolizumab in Combination with Pemetrexed/Platinum (Carboplatin or Cisplatin) Followed by Pembrolizumab and Maintenance Olaparib vs Maintenance Pemetrexed in the First-Line Treatment of Participants with Metastatic Nonsquamous Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new ways to treat advanced lung cancer. It combines standard chemotherapy with newer drugs, pembrolizumab and olaparib, to see if this mix works better than current treatments in slowing down cancer growth and helping people live longer and feel better.
For: Stage IV lung cancer conditionRomania · Austria · Germany - RecruitingPHASE1, PHASE2
A Clinical Study of Raludotatug Deruxtecan in People With Ovarian Cancer (MK-5909-003)
This study looks at new ways to treat ovarian cancer that has come back after earlier treatments. It tests a new drug called Raludotatug deruxtecan (R-DXd) by itself or with other standard treatments, to see if it's safe and helps shrink the cancer.
For: Ovarian Cancer RecurrentUnited States · Israel · Spain - RecruitingPHASE3
A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)
This study looks at a new drug, sevabertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares sevabertinib to standard treatments to see if it works better and is safe.
For: Advanced Non-small Cell Lung Cancer · HER2 MutationUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Randomized, Open Label Phase II Clinical Trial of BMS-986012 in Combination with Carboplatin, Etoposide and Nivolumab as First-line Therapy in Extensive-Stage Small Cell Lung Cancer
This study is looking at a new treatment combination for a type of lung cancer called extensive-stage small cell lung cancer. It combines an approved drug (Nivolumab, also known as OPDIVO) with two standard chemotherapy drugs and a new study drug, BMS-986012, to see if it helps patients.
For: Extensive-stage Small Cell Lung CancerRomania · Spain · Belgium - Not yet recruitingPHASE3
DAREON®-NEC-1: A Study in People With Advanced Extrapulmonary Neuroendocrine Cancer to Compare Obrixtamig Plus Carboplatin and Etoposide Treatment With Standard Chemotherapy
This study for advanced neuroendocrine cancer compares a new drug called obrixtamig with standard chemotherapy. It aims to see if adding obrixtamig helps people live longer and also tests a new device to measure a cancer marker.
For: Extrapulmonary Neuroendocrine CancerUnited States · Argentina · Australia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Open-Label Clinical Study to Evaluate the Efficacy and Safety of Pembrolizumab plus Epacadostat, Pembrolizumab Monotherapy, and the EXTREME Regimen as First line Treatment for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (KEYNOTE-669/ECHO-304)
This study looks at new treatments for a type of head and neck cancer that has come back or spread. It compares an immunotherapy drug called pembrolizumab, alone or with another drug called epacadostat, against a standard treatment.
For: Histologically or cytologically-confirmed Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma that is considered incurable by local therapiesPortugal · Spain - RecruitingPHASE3
Pembrolizumab With or Without Maintenance Sacituzumab Tirumotecan (Sac-TMT; MK-2870) in Metastatic Squamous Non-small Cell Lung Cancer (NSCLC) [MK-2870-023]
This study looks at new ways to treat advanced squamous non-small cell lung cancer. It combines standard treatment (Pembrolizumab, Carboplatin, Paclitaxel/Nab-paclitaxel) with a new drug, sac-TMT, to see if it helps people live longer.
For: Non-small Cell Lung Cancer · NSCLCUnited States · Argentina · Austria - Active not recruitingPHASE1
Study of Amivantamab, a Human Bispecific EGFR and cMet Antibody, in Participants With Advanced Non-Small Cell Lung Cancer
This study looks at a new drug, Amivantamab, alone or with other treatments, for certain types of advanced lung cancer. We want to find the safest and most effective dose, and see how well it works.
For: Non-Small-Cell Lung CancerUnited States · Australia · Canada - RecruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
For: Endometrial Cancer · Gastric Cancer · Metastatic Castration-resistant Prostate CancerUnited States · Canada · China - RecruitingPHASE1
Clinical Trial Evaluating the Safety, Tolerability and Preliminary Efficacy of BNT116 Alone and in Combinations in Patients With Advanced Non-small Cell Lung Cancer
This study looks at a new drug, BNT116, for advanced lung cancer. It explores if BNT116 is safe, how much to give, and how well it works when used alone or with other treatments for different types of non-small cell lung cancer.
For: Non-Small Cell Lung CancerUnited States · Australia · Germany - Active not recruitingPHASE2
Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Substudy-01
This study is testing new combinations of treatments for head and neck cancer that has come back or spread. It compares two new drugs plus chemotherapy against one new drug plus chemotherapy. The aim is to find safer and more effective ways to treat this type of cancer.
For: Head and Neck Squamous Cell CarcinomaUnited States · Australia · China - RecruitingPHASE2, PHASE3
A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma
This study looks for better ways to treat B-cell non-Hodgkin Lymphoma (B-NHL) in children and young people when initial treatments haven't worked or the cancer has returned. It tests new medicines to see if they are safe and effective, aiming to improve chances of recovery.
For: B-cell Non Hodgkin LymphomaAustralia · Austria · Belgium - Active not recruitingPHASE3
A Study of Neoadjuvant Chemotherapy Plus Nivolumab Versus Neoadjuvant Chemotherapy Plus Placebo, Followed by Surgical Removal and Adjuvant Treatment With Nivolumab or Placebo for Participants With Surgically Removable Early Stage Non-small Cell Lung Cancer
This study is looking at a new treatment for early-stage lung cancer that can be removed with surgery. It combines standard chemotherapy with a newer drug called nivolumab. Researchers want to see if this combination helps people live longer without their cancer returning.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - RecruitingPHASE3
A Study to Compare Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone as Treatment in Participants With Mismatch Repair Proficient Endometrial Cancer (MK-2870-033/TroFuse-033/GOG-3119/ENGOT-en29)
This study looks at new treatments for a type of womb cancer that has spread or returned. It compares a new drug combination (sac-TMT with pembrolizumab) against pembrolizumab alone to see if it helps patients live longer and keeps the cancer from growing.
For: Endometrial CancerUnited States · Argentina · Australia - RecruitingPHASE3
A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
This study looks at new drug combinations for a specific type of advanced lung cancer. It compares a new drug, Divarasib, with Pembrolizumab, against standard treatments to see which works best and is safest for patients with KRAS G12C-mutated non-small cell lung cancer.
For: Non-Small Cell Lung Cancer · KRAS G12C Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Mismatch Repair Deficient (dMMR) Advanced or Recurrent Endometrial Carcinoma (MK-3475-C93/KEYNOTE-C93/GOG-3064/ENGOT-en15)
This study is looking at a new treatment called pembrolizumab for advanced or recurrent womb cancer that has a specific genetic marker. It compares this new treatment to standard chemotherapy to see which works better and is safer for women who haven't had chemotherapy for this stage of cancer before.
For: Endometrial NeoplasmsUnited States · Australia · Belgium - Active not recruitingPHASE3
A Study of Dato-DXd Versus Investigator's Choice Chemotherapy in Patients With Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer, Who Are Not Candidates for PD-1/PD-L1 Inhibitor Therapy (TROPION-Breast02)
This study is looking at a new medicine called Dato-DXd for advanced triple-negative breast cancer. It compares Dato-DXd with standard chemotherapy in patients who cannot have a specific type of immunotherapy. The aim is to see if Dato-DXd is better at shrinking tumours and helping people live longer.
For: Breast CancerUnited States · Argentina · Belgium - RecruitingPHASE2
Study of Volrustomig as Monotherapy or in Combination With Anti- Cancer Agents in Participants With Advanced/Metastatic Solid Tumors
This study is looking into a new medicine called Volrustomig for various advanced cancers, including cervical, head and neck, oesophageal, and mesothelioma. It aims to see how well it works and if it's safe, both on its own and with standard chemotherapy.
For: Sub-study 1 Cervical Cancer (Volrustomig Monotherapy) · Sub-study 2 Head and Neck Squamous Cell Carcinoma (Volrustomig Monotherapy) · Sub-study 3 Head and Neck Squamous Cell Carcinoma (Volrustomig in Combination With Chemotherapy)United States · Australia · Brazil - Active not recruitingPHASE3
Standard-Dose Combination Chemotherapy or High-Dose Combination Chemotherapy and Stem Cell Transplant in Treating Patients with Relapsed or Refractory Germ Cell Tumors
This study compares two chemotherapy treatments for germ cell tumours that have returned or didn't respond to previous treatment. It looks at a standard chemotherapy plan versus a stronger plan with a stem cell transplant to see which works better.
For: Germ Cell Tumor · Teratoma · ChoriocarcinomaUnited States · Australia · Belgium - Active not recruitingPHASE3
Paediatric Hepatic International Tumour Trial
This study, called PHITT, is for children and young people up to 30 years old with liver cancers called hepatoblastoma (HB) and hepatocellular carcinoma (HCC). It aims to find better ways to treat these cancers by using tailored treatments and studying them closely.
For: Hepatoblastoma · Carcinoma, HepatocellularAustria · Belgium · Czechia - RecruitingPHASE1, PHASE2
A Study Evaluating the Safety, Activity, and Pharmacokinetics of Divarasib as a Single Agent or in Combination With Other Anti-Cancer Therapies in Participants With Previously Untreated Advanced or Metastatic Non-Small Cell Lung Cancer With a KRAS G12C Mutation
This study looks at a new drug, Divarasib, for advanced lung cancer with a specific gene change (KRAS G12C). It checks if the drug is safe, how it works, and if it can shrink tumours, either alone or with other cancer treatments.
For: Non-Small Cell Lung CancerUnited States · Argentina · Australia - RecruitingPHASE1
Phase 1 Study of INBRX-109 in Subjects With Locally Advanced or Metastatic Solid Tumors Including Sarcomas
This early-stage study is testing a new drug, INBRX-109, for people with advanced solid tumours, including certain types of Ewing sarcoma and bowel cancer. Researchers want to see if it's safe and how well it works, both alone and with standard treatments. This is for patients who haven't responded to previous therapies.
For: Ewing Sarcoma · Colorectal AdenocarcinomaUnited States · France · Italy - RecruitingPHASE3
A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)
This study looks at new treatments, sacituzumab tirumotecan alone or with pembrolizumab, for triple-negative breast cancer. It compares their effectiveness with standard chemotherapy to see if they help people live longer or stop cancer growth.
For: Triple Negative Breast NeoplasmsUnited States · Argentina · Australia - Active not recruitingPHASE3
A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast Cancer
This study is looking at new ways to treat a type of breast cancer that doesn't have certain hormone receptors or HER2 protein, called triple-negative or hormone receptor-low/HER2-negative breast cancer. It tests two different treatment plans using new and existing medicines before and after surgery.
For: Breast CancerUnited States · Australia · Austria - Active not recruitingPHASE2
Study of Sacituzumab Govitecan Combinations in First-line Treatment of Participants With Advanced or Metastatic Non-Small-Cell Lung Cancer (NSCLC)
This study is looking at new combinations of medicines for advanced lung cancer that has spread. It combines a drug called sacituzumab govitecan (SG) with pembrolizumab, and sometimes with chemotherapy agents like carboplatin or cisplatin, to see how well they work together.
For: Non-small Cell Lung CancerUnited States · Australia · Canada - RecruitingPHASE3
A Study of First-Line Olomorasib (LY3537982) and Pembrolizumab With or Without Chemotherapy in Patients With Advanced KRAS G12C-Mutant Non-small Cell Lung Cancer
This study looks at a new drug, olomorasib, combined with other treatments for advanced lung cancer. It’s for people whose cancer has a specific change called KRAS G12C and haven't had previous treatment for advanced disease. The aim is to see if this new combination works better than standard care.
For: Carcinoma, Non-Small-Cell Lung · Neoplasm MetastasisUnited States · Australia · Austria - RecruitingPHASE2, PHASE3
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
This study is testing a new drug called pumitamig, combined with usual chemotherapy and other drugs, for people with a type of lung cancer called non-small cell lung cancer. It aims to see if this new combination is safe and works well.
For: Non-small Cell Lung CancerUnited States · Australia · Belgium - RecruitingPHASE3
A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
This study looks at a new treatment called intismeran autogene, given with pembrolizumab, after surgery for non-small cell lung cancer. We want to see if this combination stops the cancer from coming back compared to pembrolizumab alone.
For: Carcinoma, Non-Small-Cell LungUnited States · Argentina · Australia - Active not recruitingPHASE2
Pembrolizumab in Combination With R-ICE Chemotherapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma
This study looks at a new combination of treatments for a type of lymphoma called diffuse large B-cell lymphoma. It combines standard chemotherapy with a newer drug called pembrolizumab to see if it works better for people whose lymphoma has come back or hasn't responded to previous treatment.
For: Diffuse Large B Cell LymphomaUnited Kingdom - Active not recruitingPHASE3
Polatuzumab Vedotin Plus Rituximab, Ifosfamide, Carboplatin and Etoposide (Pola-R-ICE) Versus R-ICE Alone in Second Line Treatment of Diffuse Large B-cell Lymphoma (DLBCL)
This study compares two treatments for a type of blood cancer called Diffuse Large B-cell Lymphoma (DLBCL) that has come back or not responded well to initial treatment. One treatment is a standard chemotherapy, and the other adds a new drug, polatuzumab vedotin, to that standard treatment.
For: Relapsed Diffuse Large B-cell Lymphoma · Refractory Diffuse Large B-Cell LymphomaAustria · Germany · Spain - Active not recruitingPHASE3
Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment
This study looks at a new drug, zongertinib, for advanced lung cancer with a specific genetic change (HER2 mutation). It compares zongertinib to standard treatment to see if it can better slow down cancer growth and improve how long people live without their cancer getting worse.
For: Lung Cancer, Non-squamous, Non-small CellUnited States · Argentina · Australia - RecruitingPHASE2, PHASE3
Phase 2/3 Trial of Izalontamab Brengitecan vs Platinum-based Chemotherapy for Metastatic Urothelial Cancer With Disease Progression on or After Immunotherapy
This study compares a new medicine, Iza-bren, with standard chemotherapy for advanced bladder cancer that has worsened after immunotherapy. It aims to see if Iza-bren is a better option for people who have already had certain treatments for their cancer.
For: Urothelial CancerUnited States · Argentina · Australia - Active not recruitingPHASE3
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer
This study is for people with a specific type of advanced breast cancer (PD-L1 positive triple-negative) that hasn't been treated yet. It compares two different drug combinations to see which one works better at stopping the cancer from growing.
For: Triple Negative Breast Cancer · PD-L1 PositiveUnited States · Argentina · Australia - Active not recruitingPHASE2
A Study of Relatlimab Plus Nivolumab in Combination With Chemotherapy vs. Nivolumab in Combination With Chemotherapy as First Line Treatment for Participants With Stage IV or Recurrent Non-small Cell Lung Cancer (NSCLC)
This study looks at new drug combinations to treat advanced lung cancer. It compares two different drug mixes, each including chemotherapy, to see which works best and is safest for people with Stage IV or recurrent non-small cell lung cancer.
For: Non-small Cell Lung Cancer · Recurrent Non-small Cell Lung Cancer · Metastatic Non-small Cell Lung CancerUnited States · Argentina · Australia - Active not recruitingPHASE1, PHASE2
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab
This study is testing a new combination treatment for a type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). It aims to find a safe dose and see if this new combination works better than current treatments for people newly diagnosed with this aggressive cancer.
For: Extensive Stage Small Cell Lung CancerUnited States · Austria · Canada - RecruitingPHASE3
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
This study looks at how best to treat a type of cancer called germ cell tumours in children and adults. It compares simply watching the tumour after surgery with different chemotherapy treatments to see which works best and causes fewer side effects.
For: Childhood Extracranial Germ Cell Tumor · Extragonadal Embryonal Carcinoma · Germ Cell TumorUnited States · Australia · Canada - Active not recruitingPHASE3
Disitamab Vedotin With Pembrolizumab vs Chemotherapy in Previously Untreated Urothelial Cancer Expressing HER2
This study looks at new treatments for bladder and related cancers that have spread. We want to see if combining two drugs, disitamab vedotin and pembrolizumab, works better than standard chemotherapy. It also checks for side effects.
For: Urothelial CarcinomaUnited States · Argentina · Australia